Do nuclear import enhancers reduce or exacerbate nuclear TDP-43 aggregation in compromised nuclear environments?

The debate revealed conflicting predictions about whether enhancing nuclear import would help or harm when nuclear TDP-43 pathology already exists. This fundamental question determines therapeutic viability of importin-targeting approaches.

Source: Debate session sess_SDA-2026-04-11-sda-2026-04-01-gap-006 (Analysis: SDA-2026-04-11-sda-2026-04-01-gap-006)

Resolved when an evidence artifact resolves whether nuclear import enhancers reduce or exacerbate nuclear TDP-43 aggregation in compromised nuclear environments, with one of: (1) cellular studies in TDP-43 aggregation models (TDP-43 Q331K, C90RF72 GGGGCC expansion, or chronic oxidative stress) treated with nuclear import enhancers (importin inhibitors or small molecules), demonstrating >=30% change in nuclear TDP-43 solubility (biochemical fractionation) and >=30% change in aggregate number/size (fluorescence microscopy, ThS staining); (2) iPSC-derived neurons from ALS-FTD patients with TDP-43 pathology treated with >=2 nuclear import enhancers (e.g., csiA, XC-2, or Importin-targeting compounds), measuring nuclear TDP-43 levels (nuclear fractionation + western blot) and neuronal viability (MTT or Caspase 3/7) with n >= 3 patient lines per condition; (3) mechanistic studies establishing whether import enhancement worsens nuclear import of aggregation-prone TDP-43 fragments or whether it promotes clearance via nuclear export or autophagy. The artifact must include both positive and negative readouts before closure.

Resolved by hypothesis h-ccc05373: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance. Score: 0.879. Supporting PMIDs: 39817908, NCT05869669, 39817908, NCT05869669, 39817908.